Nicox and Ocumension Therapeutics announced an exclusive license agreement to develop and commercialize NCX 470, Nicox’s product candidate for glaucoma and ocular hypertension, in mainland China, Hong Kong, Macau and Taiwan.
NCX 470 is designed to release bimatoprost and nitric oxide after instillation in the eye to reduce IOP in patients with open-angle glaucoma and ocular hypertension, according to a press release.
Ocumension will develop and commercialize NCX 470, at its own cost, for a one-time upfront payment of 3 million euros to Nicox and 2.5 million euros when Nicox
Uncategorized